Founded and SBIR involved as NexBio, Inc., in 2014 the firm was renamed Ansun Biophama. Now with significant eternal funding, the firm is organized around development of a novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infectionss. Its products include Fludase, a drug candidate for the prophylaxis and treatment of respiratory infections caused by various types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as various types of parainfluenza virus. The company's products also include Viradin, an intravenous therapeutic for sepsis and septic shock, as well as viral hemorrhagic fever caused by such pathogens as Ebola and Marburg viruses. In addition, its products include TOSAP, a formulation technology capable of creating microspheres and nanospheres for drug delivery.
